Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated:  10/22/2015
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated: 10/22/2015
Montefiore Medical Center, Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated:  10/22/2015
Monter Cancer Center
mi
from
Lake Success, NY
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated: 10/22/2015
Monter Cancer Center
mi
from
Lake Success, NY
Click here to add this to my saved trials
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated:  10/22/2015
Columbia University Medical Center
mi
from
New York, NY
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated: 10/22/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated:  10/22/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated: 10/22/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated:  10/22/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated: 10/22/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated:  10/22/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated: 10/22/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated:  10/22/2015
Texas Oncology, PA
mi
from
Dallas, TX
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated: 10/22/2015
Texas Oncology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated:  10/22/2015
Tom Baker Cancer Center
mi
from
Calgary,
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma
Status: Enrolling
Updated: 10/22/2015
Tom Baker Cancer Center
mi
from
Calgary,
Click here to add this to my saved trials
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
Midwest Center for Hematology/Oncology
mi
from
Joliet, IL
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
Midwest Center for Hematology/Oncology
mi
from
Joliet, IL
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
Cardinal Bernardin Cancer Center at Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
CCOP - Cancer Research for the Ozarks
mi
from
Springfield, MO
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
CCOP - Cancer Research for the Ozarks
mi
from
Springfield, MO
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
St. John's Regional Health Center
mi
from
Springfield, MO
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
St. John's Regional Health Center
mi
from
Springfield, MO
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
Good Samaritan Hospital Cancer Treatment Center
mi
from
Cincinnati, OH
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
Good Samaritan Hospital Cancer Treatment Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
Bethesda North Hospital
mi
from
Cincinnati, OH
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
Bethesda North Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
Tod Children's Hospital
mi
from
Youngstown, OH
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
Tod Children's Hospital
mi
from
Youngstown, OH
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
LaFortune Cancer Center at St. John Medical Center
mi
from
Tulsa, OK
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
LaFortune Cancer Center at St. John Medical Center
mi
from
Tulsa, OK
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
Geisinger Medical Center
mi
from
Danville, PA
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
Geisinger Medical Group - Scenery Park
mi
from
State College, PA
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated:  10/23/2015
U.T. Cancer Institute at University of Tennessee Medical Center
mi
from
Knoxville, TN
S0000 Selenium and Vitamin E in Preventing Prostate Cancer
Selenium and Vitamin E Cancer Prevention Trial (SELECT) for Prostate Cancer
Status: Enrolling
Updated: 10/23/2015
U.T. Cancer Institute at University of Tennessee Medical Center
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated:  10/24/2015
Westside Prostate Cancer Center, University of Southern California
mi
from
Beverly Hills, CA
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated: 10/24/2015
Westside Prostate Cancer Center, University of Southern California
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated:  10/24/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab in Patients With Metastatic Androgen Independent Prostate Cancer
Status: Enrolling
Updated: 10/24/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Los Angeles, CA
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Roseville, CA
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Roseville, CA
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Tampa, FL
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
New Orleans, LA
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
St. Louis, MO
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Las Vegas, NV
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
Clinical Research Facility
mi
from
Philadelphia, PA
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated:  10/26/2015
mi
from
Liverpool,
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Status: Enrolling
Updated: 10/26/2015
mi
from
Liverpool,
Click here to add this to my saved trials
Positron Emission Tomography in Prostate Cancer
Positron Emission Tomography in Prostate Cancer
Status: Enrolling
Updated:  10/28/2015
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Positron Emission Tomography in Prostate Cancer
Positron Emission Tomography in Prostate Cancer
Status: Enrolling
Updated: 10/28/2015
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer
Phase II Trial of Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer
Status: Enrolling
Updated:  10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer
Phase II Trial of Exogenous Testosterone Plus Dutasteride for the Treatment of Castrate Metastatic Prostate Cancer
Status: Enrolling
Updated: 10/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated:  11/3/2015
Aurora St. Luke's Hospital
mi
from
Milwaukee, WI
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated: 11/3/2015
Aurora St. Luke's Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated:  11/3/2015
Aurora West Allis
mi
from
West Allis, WI
Effect of Cancer Nurse Navigators on Patient Outcomes
Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes
Status: Enrolling
Updated: 11/3/2015
Aurora West Allis
mi
from
West Allis, WI
Click here to add this to my saved trials
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated:  11/4/2015
University of Michigan
mi
from
Ann Arbor, MI
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated: 11/4/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated:  11/4/2015
University of Rochester
mi
from
Rochester, NY
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated: 11/4/2015
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated:  11/4/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)
Status: Enrolling
Updated: 11/4/2015
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Prostate Cancer Localization With a Multiparametric MR Approach
Status: Enrolling
Updated:  11/9/2015
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Prostate Cancer Localization With a Multiparametric MR Approach
Status: Enrolling
Updated: 11/9/2015
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Prostate Cancer Localization With a Multiparametric MR Approach
Status: Enrolling
Updated:  11/9/2015
Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Prostate Cancer Localization With a Multiparametric MR Approach
Status: Enrolling
Updated: 11/9/2015
Johns Hopkins Medical Institutions
mi
from
Baltimore, MD
Click here to add this to my saved trials
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Prostate Cancer Localization With a Multiparametric MR Approach
Status: Enrolling
Updated:  11/9/2015
Medical University of Vienna
mi
from
Vienna,
Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach
Prostate Cancer Localization With a Multiparametric MR Approach
Status: Enrolling
Updated: 11/9/2015
Medical University of Vienna
mi
from
Vienna,
Click here to add this to my saved trials
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
New Orleans, LA
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Detroit, MI
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Houston, TX
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Pleasant Hill, CA
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Pleasant Hill, CA
Click here to add this to my saved trials
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Chicago, IL
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
New Brunswick, NJ
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated:  11/9/2015
Clinical Research Facility
mi
from
Cleveland, OH
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial Investigating Two Doses of EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer (mCRPC)
Status: Enrolling
Updated: 11/9/2015
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials